Posted by Michael Wonder on 31 Aug 2021
Teva and MedinCell announce FDA acceptance of new drug application for TV-46000/mdc-IRM as a treatment for patients with schizophrenia
31 August 2021 - File acceptance marks important milestone for Teva’s commitment to treatments for mental disorders
Teva Pharmaceuticals and MedinCell announced today that the new drug application for TV-46000/mdc-IRM (risperidone extended release injectable suspension for subcutaneous use) for the treatment of schizophrenia has been accepted by the U.S. FDA.
